Phase II study of etoposide for carcinoma of the prostate

P. J. Walther, S. D. Williams, M. Troner, F. A. Greco, R. Birch, L. H. Einhorn

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


The treatment of prostate carcinoma with the epipodophyllotoxin derivative etoposide was studied in a multi-institutional phase II trial. An iv dose schedule of 130 mg/m2 daily for 3 days every 3 weeks was utilized. A total of 36 patients were evaluable; the observed total response was 3%. Moderate toxicity (predominantly myelosuppression) was seen utilizing this treatment schedule. It is concluded that etoposide possesses little single-agent therapeutic activity for prostate carcinoma.

Original languageEnglish (US)
Pages (from-to)771-772
Number of pages2
JournalCancer Treatment Reports
Issue number6
StatePublished - 1986

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II study of etoposide for carcinoma of the prostate'. Together they form a unique fingerprint.

Cite this